This review aimed to assess the value of B-type natriuretic peptide (BNP) measurements for managing patients with congestive heart failure. The authors concluded that BNP determinations are useful in a limited number of clinical scenarios. However, since the review was poorly reported and suffered from methodological weaknesses, the conclusions should be interpreted with caution.
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction.
Methods of synthesis
How were the studies combined? A narrative synthesis of the studies was undertaken.
How were differences between studies investigated? Some differences between the studies were discussed.
Results of the review
The authors reported the results of four diagnostic accuracy studies (n=2,279) in the tables and main section of results, while two further diagnostic accuracy studies were referred to in the text of the 'Results' section. It is therefore unclear exactly how many studies met the inclusion criteria.
Three studies that used a cut-point of 76 to 80 pg/mL BNP to diagnose congestive heart failure reported sensitivities ranging from 93 to 98%, with corresponding specificities ranging from 74 to 92%. One study used a cut-point of 94 pg/mL BNP to differentiate dyspnoea caused by heart failure from pulmonary causes and found a sensitivity of 86% and a specificity of 98%. One study reported that the mean BNP levels increased with increased New York Heart Association class.
